HRC
Get informed when a big investor buys or sells
+ FollowUndervalued by 2.6% based on the discounted cash flow analysis.
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $3.58 Billion |
| Dividend Yield | $17.74 (0.60%) |
| Earnings per Share | $3.72 |
| Beta | 0.55 |
| Outstanding Shares | 66,267,000 |
| P/E Ratio | 41.95 |
|---|---|
| PEG | 27.62 |
| Price to Sales | 1.71 |
| Price to Book Ratio | 2.79 |
| Enterprise Value to Revenue | 0.59 |
| Enterprise Value to EBIT | 4 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 1.15 |
| Debt to Equity | 1.1 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
This most powerful economic committee controls taxation, trade, and entitlement spending (Medicare/Medicaid), which directly influences corporate profitability, healthcare funding, and demand for medical devices.
This committee directly allocates discretionary federal spending across all government functions, including healthcare programs and agencies that purchase or fund medical instruments, profoundly impacting Hill-Rom's market.
This committee directly oversees the FDA, which regulates medical device approvals and safety, and influences labor laws that impact manufacturing costs, making its impact critical for Hill-Rom.
This committee directly oversees the Department of Veterans Affairs, a major buyer of medical equipment for VA hospitals, thus significantly impacting a key customer segment for Hill-Rom.